The laboratory tablet, which will be marketed under the name Paxlovid, reduces hospitalizations by at-risk, based on clinical trials by about 89%, according to clinical trials.
Le Monde via AP and AFP
The Pfizer laboratory, already at the origin of one of the most used COVID-19 vaccines in the world, said Tuesday, December 14 that this new antiviral showed very encouraging results against CVIV-19 . According to the latest clinical trials, it reduces the risks of hospitalization and death by at risk, if it is taken in the early days after the appearance of symptoms.
These results are based on all test participants, more than 2,200 people, and confirm what was announced in early November from preliminary results. No deaths were recorded among those who received the treatment. Participants were non-vaccinated and had a high risk of developing a serious case of COVID-19, due to their advanced age or health problems, such as asthma or obesity.
Hope against The Omicron Variant
Pfizer also announced that its antiviral treatment, which will be marketed under the name of Paxlovid, should remain effective against the Omicron variant. To make sure it, Pfizer has tested his medicine against an artificial version of a key protein that Omicron uses to reproduce. “This highlights the potential of this candidate [-Medicament] to save patient lives in the world,” said Albert Bourla, the Pfizer CEO, cited in a communiqué . “Concern’s variants like Omicron have exacerbated the need for accessible solutions for those who contract the virus,” he added.